Compare Novavax Inc (NVAX) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs Procter & Gamble Co — how do they compare? Novavax Inc trades at $9.86 (market cap $1.68B), while Procter & Gamble Co trades at $143.11 (market cap $338.13B). The key difference: Procter & Gamble Co is far larger — about 201.3× Novavax Inc's market cap, and Procter & Gamble Co pays a 2.99% dividend while Novavax Inc pays none. Which is the better fit depends on your goals.
| NVAX | PG | |
|---|---|---|
Market Cap | $1.68B | $338.13B |
Sector | Health | Consumer Staples |
52-Week High | $11.19 | $167.18 |
52-Week Low | $6.22 | $138.10 |
Enterprise Value | $1.26B | $363.97B |
Volume | — | 6,423,436 |
Dividend Yield | — | 2.99% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $10.19, down 0.29% today, with a bullish technical signal from moving averages but overbought RSI levels. Recent Q2 2026 earnings beat expectations, and the company raised its 2026 revenue outlook. Key developments include regulatory approvals for its updated COVID-19 vaccine in the U.S., EU, and Japan for the 2026-2027 season, alongside ongoing partnerships with Sanofi and Pfizer.
The outlook is mixed: strong analyst buy ratings (73.9%) and partnership milestones offer upside, but negative net income margins and cash flow challenges pose risks. Investors should weigh the potential from vaccine demand and adjuvant platform royalties against financial sustainability concerns and competitive pressures in the biotech sector.
Procter & Gamble (PG) trades at $145.59, down 0.57% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong earnings beats in recent quarters and maintains robust profitability with a net margin of 18.44% and ROE of 30.13%. Recent news highlights its dividend reliability and supply chain enhancements, while analyst consensus leans bullish with a $162.50 price target.
PG offers steady growth and income appeal with a 69-year dividend growth streak, but premium valuation and soft demand outlook pose near-term risks. Upside hinges on execution amid economic pressures, with support at $143 and resistance at $146.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
